Investment
Features
FeesSafety
Academy
More
Pluang+

Bitcoin held since 2013 worth $54K now moved, valued over $30M in new wallet.

Market News
19 Oct 2026
Tokenpost
View Source
Neutral
Bitcoin held since 2013 worth $54K now moved, valued over $30M in new wallet.

A Bitcoin position bought in 2013 for about $54,000 has been moved to a new wallet on October 19, 2023. Originally purchased when Bitcoin was priced near $130, the coins are now worth more than $30 million. This move highlights the long-term value growth of Bitcoin over roughly 13 years and may indicate activity from a long-term holder or investor.

Bitcoin wallet activity is the subject, with Pluang market data providing context. For readers following major cryptocurrencies, 23 of 50 rose and 25 fell today. Notable movers include AXS at Rp18.020 down 1.83%, AAVE at Rp2.711.732 down 1.75%, and MANA at Rp1.511 down 1.63%. This snapshot is as of Oct 19, 2026 18:21 WIB.

More News

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...

Others
Neutral
55 minutes ago
EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...

Company Fundamentals
Neutral
55 minutes ago
Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

Market News
Bullish
55 minutes ago
Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics announced that Mark Vale, former UPS president and current CEO of Transportation Insight, will join its board and chair the audit committee after its merger with Churchill Capital Corp XI. Vale's extensive experience in global logist...

Company Fundamentals
Bullish
55 minutes ago
JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Market News
Bullish
55 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App